SeaStar Medical Announces Late-Breaking Presentation at ASN Kidney Week 2026
Globe Newswire (Fri, 2-Oct 9:43 AM ET)
Globe Newswire (Thu, 1-Oct 8:21 AM ET)
Globe Newswire (Tue, 29-Sep 8:36 AM ET)
Market Chameleon (Thu, 24-Sep 7:53 AM ET)
Globe Newswire (Thu, 24-Sep 8:16 AM ET)
SeaStar Medical to Present at the HC Wainwright 28th Annual Global Investment Conference
Globe Newswire (Thu, 10-Sep 8:35 AM ET)
SeaStar Medical Reports Second Quarter 2026 Financial Results and Provides Business Updates
Globe Newswire (Wed, 12-Aug 4:05 PM ET)
SeaStar Medical to Report Second Quarter Financial Results on August 12, 2026
Globe Newswire (Thu, 6-Aug 8:35 AM ET)
Globe Newswire (Tue, 14-Jul 8:34 AM ET)
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.
Seastar Medical Holding trades on the NASDAQ stock market under the symbol ICU.
As of October 2, 2026, ICU stock price climbed to $4.54 with 342,127 million shares trading.
ICU has a beta of 2.90, meaning it tends to be more sensitive to market movements. ICU has a correlation of 0.11 to the broad based SPY ETF.
ICU has a market cap of $20.01 million. This is considered a Sub-Micro Cap stock.
Last quarter Seastar Medical Holding reported $615,000 in Revenue and -$.91 earnings per share. This beat revenue expectation by $125,800 and exceeded earnings estimates by $.05.
In the last 3 years, ICU traded as high as $429.23 and as low as $2.07.
The top ETF exchange traded funds that ICU belongs to (by Net Assets): VXF, DXUV, DFAC.
ICU has underperformed the market in the last year with a return of -27.2%, while the SPY ETF gained +16.1%. In the last 3 month period, ICU fell short of the market, returning -6.6%, while SPY returned +3.3%. However, in the most recent 2 weeks ICU has outperformed the stock market by returning +29.8%, while SPY returned +1.3%.
ICU support price is $3.53 and resistance is $3.97 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ICU shares will trade within this expected range on the day.